Intensified treatment options and considerations in mHSPC
Detta event är kostnadsfritt för deltagare. Bayer står för arvode till föreläsarna.
On behalf of the Scientific Committee and the Nordic Bayer Oncology team we welcome you to attend this webinar
Intensified treatment options and considerations in mHSPC
A rapid evolvement of treatment options in the mHSPC space raises questions on how to choose the optimal medical treatment for each individual patient. With numerous options comes numerous questions; What to give to whom and when? Prof Matthew Smith will present data relevant for intensified treatment approaches, in the context of other treatment modalities. The presentation will be followed by a discussion with the panel on how to navigate in the current treatment landscape, and a live Q&A with the audience.
Speaker Prof Matthew R. Smith, Professor of Medicine, Harvard Medical School Massachusetts General Hospital Cancer Center, Boston, USA
Scientific committee: Chair Dr Daniel Heinrich (Norway), Prof Andreas Røder (Denmark), Dr Camilla Thellenberg Karlsson (Sweden), Dr Niilo Hendolin (Finland), Dr Marius Kinčius (Lithuania)
Agenda
12:00 Welcome and introduction – setting the Nordic scene (Daniel Heinrich)
12:10 The role of intensified treatment in mHSPC patients – identification of the right treatment option for the right patient (Matthew R. Smith)
12:50 Panel discussion and live Q&A (All)
13:15 Meeting closure
For assistance regarding registration please contact; Carina Bajer, Business Support Specialist, [email protected], +46 70-862 04 51
For medical questions please contact; Lena Thyrell, Sr. Medical Advisor, [email protected],
+46 76-851 53 37
Use the link below to sign up for the webinar:
PP-NUB-SE-0167-1
